Goodman to build four data centre projects in Europe Construction expected to start by June 30, 2026 Goodman Group shares hit highest level since Nov 5 Dec 23 (Reuters) - Australia's Goodman Group ...
A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics. His stories explore how tech is changing the ...
From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...
Journal Editorial Report: The Fed Chief signals rate cuts are coming. As we saw during the Covid pandemic, lab-created experiments can wreak havoc when they escape their confines. Once released, they ...
Windows Thanks to Microsoft adding all those extra features to Notepad, it now unfortunately sports one more: An exploitation vulnerability with a high security rating AI Microsoft AI CEO curiously ...
The new ‘COPILOT’ function uses AI to generate summaries, tags, tables, and more based on a group of cells. The new ‘COPILOT’ function uses AI to generate summaries, tags, tables, and more based on a ...
The new AI function in Sheets can generate text for groups of cells based on their contents. The new AI function in Sheets can generate text for groups of cells based on their contents. is a news ...
Gain-of-function research became controversial during the COVID-19 pandemic. But without it, “we’re just flying in the dark” when it comes to H5N1, said Felicia Goodrum, a molecular virologist at the ...
As a person with a chronic illness, I'm no stranger to bloodwork. I used to pore over my lab results, googling the various meanings, and trying not to panic when a test fell out of range. Function ...
Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHas) is a standard of care for premenopausal patients with high-risk stage II/III hormone receptor–positive breast ...